Bessemer Group
KDNY

Bessemer Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Bessemer Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-22
Closed -$1K – 2090
2016
Q3 		$1K Sell
22
-1
-4% -$71 ﹤0.01% 1778
2016
Q2 		$1K Hold
23
– – ﹤0.01% 1281
2016
Q1 		$2K Buy
23
+7
+44% +$566 ﹤0.01% 1401
2015
Q4 		$2K Buy
+16
New +$2.17K ﹤0.01% 1507

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bessemer Group's KDNY Position: Q4 2016 in Review

Bessemer Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2016, closing a stake of 22 shares — an estimated $1K sold.

Bessemer Group first reported a position in KDNY in Q4 2015 and held it in 4 quarters. The position peaked at $2K in Q1 2016. 87 funds tracked by Wall St. Rank hold KDNY as of Q4 2016.

  • Bessemer Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Bessemer Group sold 22 Chinook Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $1K.
  • Bessemer Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
  • Bessemer Group's Chinook Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2016.
  • 87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Bessemer Group's 13F filing for Q4 2016, filed 7 Feb 2017.